Highly Sensitized Patients on Waiting List for Kidney Transplantation

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Highly Sensitized Patients on Waiting List for Kidney Transplantation trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 1

NCT06056102

CAR-T Cell Therapy for Desensitization in Kidney Transplantation

This research study is for people who have been waiting for a kidney transplant for at least one year, and who have a cPRA of 99.5% or higher. Having a cPRA of…

United States20 participantsStarted 2024-05-09

Treatment: Cyclophosphamide, CART-BCMA

All recent trials (3 shown)

WithdrawnPhase 2

NCT04174677

Safety and Tolerability of Inebilizumab, VIB4920, or the Combination in Highly Sensitized Candidates Awaiting Kidney Tra…

Viela Bio is conducting an open-label, randomized study of inebilizumab, VIB4920, or the combination as part of a multi-center study in highly sensitized patien…

United States0Started 2019-12-27

Treatment: Inebilizumab, VIB4920

UnknownPhase 2

NCT01502267

Desensitization Protocol for Highly Sensitized Patients on the Waiting List for Kidney Transplant

The purpose of this study is to determine whether high dose IVIG and B cell depleting agents can be used effectively in highly sensitized wait-listed patients.

South Korea2 participantsStarted 2010-01

Treatment: High dose IVIG and B cell depleting agents